## EDITORIAL

3368 Remazolam combined with transversus abdominis plane block in gastrointestinal tumor surgery: Have we achieved better anesthetic effects?
*Cao J, Luo XL, Lin Q*

3372 Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer
*Gao L, Lin Q*

3376 Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy
*Yu JM, Sun CQ, Xu HH, Jiang YL, Jiang XY, Ni SQ, Zhao TY, Liu LX*

3382 Importance of early detection of esophageal cancer before the tumor progresses too much for effective treatment
*Ono T*

3386 Early diagnosis of esophageal cancer: How to put “early detection” into effect?
*Pubu S, Zhang JW, Yang J*

3393 Colon cancer screening: What to choose?
*Gomez Zuleta MA*

## REVIEW

3397 Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review
*Wei WJ, Hong YL, Deng Y, Wang GL, Qiu JT, Pan F*

3410 Research progress on the effect of pyroptosis on the occurrence, development, invasion and metastasis of colorectal cancer

## MINIREVIEWS

3428 Importance of diet and intestinal microbiota in the prevention of colorectal cancer - colonoscopy early screening diagnosis
*Jovandaric MZ*

## ORIGINAL ARTICLE

### Retrospective Cohort Study

3436 Analysis of vascular thrombus and clinicopathological factors in prognosis of gastric cancer: A retrospective cohort study
*Chen GY, Ren P, Gao Z, Yang HM, Jiao Y*
## Contents

**Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan**  
Zeng F, Zhang DY, Chen SJ, Chen RX, Chen C, Huang SM, Li D, Zhang XD, Chen JJ, Mo CY, Gao L, Zeng JT, Xiong JX, Chen Z, Bai FH  

**Effect of perioperative chemotherapy on resection of isolated pulmonary metastases from colorectal cancer: A single center experience**  

### Retrospective Study

**Microvascular structural changes in esophageal squamous cell carcinoma pathology according to intrapapillary capillary loop types under magnifying endoscopy**  
Shu WY, Shi YY, Huang JT, Meng LM, Zhang HJ, Cui RL, Li Y, Ding SG  

**Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma**  
Zuo MX, An C, Cao YZ, Pan JY, Xie LP, Yang XJ, Li W, Wu PH  

**Serum ferritin and the risk of early-onset colorectal cancer**  
Urback AL, Martens K, McMurry HS, Chen EY, Citti C, Sharma A, Kardosh A, Shatzel JJ  

**Combining lymph node ratio to develop prognostic models for postoperative gastric neuroendocrine neoplasm patients**  
Liu W, Wu HY, Lin JX, Qu ST, Gu YJ, Zhu JZ, Xu CF  

### Observational Study

**Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1**  

**Endoscopic detection and diagnostic strategies for minute gastric cancer: A real-world observational study**  
Ji XW, Lin J, Wang YT, Ruan JJ, Xu JH, Song K, Mao JS  

### Clinical and Translational Research

**Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and in vitro validation**  

### Basic Study

**Expression and significant roles of the long non-coding RNA CASC19/miR-491-5p/HMGA2 axis in the development of gastric cancer**  
Zhang LX, Luo PQ, Wei ZJ, Xu AM, Gao T  

**Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors**  
Li DG, Jiang JP, Chen FY, Wu W, Fu J, Wang GH, Li YB
Dysbiosis promotes recurrence of adenomatous polyps in the distal colorectum

Effect of acacetin on inhibition of apoptosis in Helicobacter pylori-infected gastric epithelial cell line
Yao QX, Li ZY, Kang HL, He X, Kang M

Curcumin for gastric cancer: Mechanism prediction via network pharmacology, docking, and in vitro experiments
Yang PH, Wei YN, Xiao BJ, Li SY, Li XL, Yang LJ, Pan HF, Chen GX

Lecithin-cholesterol acyltransferase is a potential tumor suppressor and predictive marker for hepatocellular carcinoma metastasis

Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis
Zhou SA, Zhou QM, Wu L, Chen ZH, Wu F, Chen ZR, Xu LQ, Gan BL, Jin HS, Shi N

Current trends and hotspots of depressive disorders with colorectal cancer: A bibliometric and visual study
Yan ZW, Liu YN, Xu Q, Yuan Y

Research status and hotspots of tight junctions and colorectal cancer: A bibliometric and visualization analysis
Li HM, Liu Y, Hao MD, Liang XQ, Yuan DJ, Huang WB, Li WJ, Ding L

Aggressive fibromatosis of the sigmoid colon: A case report
Yu PP, Liu XC, Yin L, Yin G

Jejunal sarcomatoid carcinoma: A case report and review of literature
Feng Q, Yu W, Feng JH, Huang Q, Xiao GX

Current and future research directions in cellular metabolism of colorectal cancer: A bibliometric analysis
Jiang BW, Zhang XH, Ma R, Luan WY, Miao YD

Risk factors for the prognosis of colon cancer
Wu CY, Ye K
ABOUT COVER
Editorial Board of *World Journal of Gastrointestinal Oncology*, Salem Youssef Mohamed, MD, Professor, Gastroenterology and Hepatology Unit, Department of Internal Medicine, Zagazig University, Zagazig 44516, Egypt. salemyousefmohamed@gmail.com

AIMS AND SCOPE
The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJGO* mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The *WJGO* is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCI, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJGO* as 2.5; JIF without journal self cites: 2.5; 5-year JIF: 2.8; JIF Rank: 71/143 in gastroenterology and hepatology; JIF Quartile: Q2; and 5-year JIF Quartile: Q2. The *WJGO*’s CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Si Zhao; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.
Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy

Jia-Mei Yu, Chong-Qi Sun, Huan-Huan Xu, Ya-Li Jiang, Xing-Yu Jiang, Si-Qi Ni, Ting-Yu Zhao, Ling-Xiang Liu

Abstract

Long non-coding RNAs (lncRNAs), with transcript lengths exceeding 200 nucleotides and little or no protein-coding capacity, have been found to impact colorectal cancer (CRC) through various biological processes. lncRNA expression can regulate autophagy, which plays dual roles in the initiation and progression of cancers, including CRC. Abnormal expression of lncRNAs is associated with the emergence of chemoresistance. Moreover, it has been confirmed that targeting autophagy through lncRNA regulation could be a viable approach for combating chemoresistance. Two recent studies titled “Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506” and “Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription” revealed novel insights into lncRNAs associated with autophagy and oxaliplatin resistance in CRC, respectively. In this editorial, we particularly focus on the regulatory role of lncRNAs in CRC-related autophagy and chemoresistance since the regulation of chemotherapeutic sensitivity by intervening with the lncRNAs involved in the autophagy process has become a promising new approach for cancer treatment.

Key Words: Long non-coding RNA; Autophagy; Chemoresistance; Oxaliplatin; Colorectal
INTRODUCTION

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related death worldwide[1]. It is paramount to extensively and intensively investigate the pathogenesis of CRC to facilitate the development of effective therapeutic strategies. Two recent studies by Li et al[2] and Zhao et al[3] have provided fresh perspectives on the molecular intricacies of CRC and presented novel therapeutic targets. Li et al[2] focused on the long non-coding RNA (lncRNA) PRNT/ZNF184/HIPK2 axis and its role in oxaliplatin resistance, while Zhao et al[3] investigated the influence of human β-defensin-1 on autophagy through the lncRNA TCONS_00014506.

LncRNAs are implicated in the onset and progression of various human malignancies, including CRC[4]. These molecules can interact with RNA-binding proteins and act as competing endogenous RNAs (ceRNAs) for microRNAs (miRNAs), which are involved in epigenetic modification of DNA and RNA, thereby affecting the expression of relevant genes. These lncRNA-mediated changes can induce or inhibit autophagy in tumour cells and mediate drug resistance[4-6].

Autophagy is a cellular process in which components such as proteins and organelles are transported to lysosomes for degradation[7]. Previous studies have shown that autophagy plays dual roles in tumorigenesis[8]. On the one hand, the expression of IncRNAs has been shown to regulate autophagy in CRC, and on the other hand, IncRNAs and autophagy have cross-regulatory and dual effects on tumours: IncRNAs can increase or decrease autophagy, and changes in autophagy can further promote or inhibit tumour growth[6].

Chemotherapy is essential for patients with locally advanced or metastatic CRC[9]. Oxaliplatin-based chemotherapy has been used worldwide as a first-line treatment for CRC[10]. However, the prognosis of CRC patients is not as satisfactory as expected. Endogenous and acquired oxaliplatin resistance is now considered a major obstacle limiting treatment success[11]. Studies have shown that IncRNAs are key factors in oxaliplatin resistance, and their dysregulation induces the activation of several signalling pathways, which ultimately leads to chemoresistance[12].

Autophagy also plays dual roles in the development of chemotherapeutic resistance, either by promoting or inhibiting resistance through many complex mechanisms, including the regulation of autophagy-related IncRNAs (ARlncRNAs)[6] (Figure 1A). In this editorial, we focus on the role of lncRNAs in the regulation of autophagy and chemoresistance in CRC and explore the feasibility of modulating chemosensitivity by interfering with lncRNAs involved in the autophagic process.

LNCRNAS REGULATE AUTOPHAGY IN CRC

The effects of lncRNAs on autophagy and the influence of lncRNA-regulated autophagy on CRC pathogenesis are complicated[13]. Inhibition of autophagy by lnc-POU3F3 in LOVO and SW480 CRC cells may enhance the malignant phenotype of CRC[14]. Similarly, the inhibition of LINC00858 induces colon cancer cell apoptosis, senescence, and autophagy. LINC00858 functions as a tumour-promoting lncRNA in colon cancer through the downregulation of WNK2[15]. Moreover, the lncRNA CPS1-IT might suppress metastasis and EMT by inhibiting hypoxia-induced autophagy through the inactivation of HIF-1α in CRC[16]. In addition, the lncRNAs SLCO4A1-AS1[17], UCA1[18], and MALAT1[19] promote autophagy through the miRNA-related axis, thus enhancing the proliferation of CRC cells. The dual regulatory role of ARlncRNAs, determined by the dual nature of autophagy, can serve as an effective therapeutic target for CRC[20].

Human β-defensin 1 (hBD-1) is a multifaceted antimicrobial peptide that acts as a tumour suppressor[21]. Zhao et al[3] verified that hBD-1 may induce autophagy in colon cancer SW620 cells by inhibiting the phosphorylation of mTOR through the lncRNA TCONS_00014506 at the cellular level. However, this study focused on a single cell line, and the impact of hBD-1 was not assessed; this is a limitation that could be addressed in future research. Moreover, an invest-
Yu JM et al. LncRNAs regulate autophagy and chemoresistance

**Figure 1** Mutual relationship between long non-coding RNAs, autophagy, and chemoresistance. A: Long non-coding RNAs (lncRNAs) can promote (blue line) or inhibit (orange line) autophagy and chemoresistance. Autophagy-related IncRNAs can positively or negatively influence drug resistance; B: LncRNAs function as competing endogenous RNAs by binding to specific microRNAs, leading to the activation of autophagy and ultimately enhancing resistance to 5-Fluorouracil, cisplatin, and oxaliplatin. lncRNA: Long non-coding RNAs; 5-FU: 5-Fluorouracil.

igation of the expression and function of TCONS_00014506 in patient-derived tumour samples could provide clinically relevant support for the in vitro findings. Bioinformatics analysis of autophagy-related differentially expressed lncRNAs was performed to offer novel insights on strategies that could complement existing treatments to potentially overcome resistance mechanisms and improve patient outcomes.

**LNCRNAs REGULATE OXALIPLATIN RESISTANCE IN CRC**

In recent years, emerging evidence has shown that lncRNAs play irreplaceable roles in drug resistance[4,6,22]. However, we have limited knowledge of the lncRNAs that are closely related to oxaliplatin resistance in CRC. A novel lncRNA, Linc00152 antagonizes oxaliplatin sensitivity by acting as a competing ceRNA to modulate the expression of miR-193a-3p and subsequently modulate the expression of erb-b2 receptor tyrosine kinase 4[23]. The lncRNAs CACS15[24], KCNQ1OT1[25], MEG3[26], CRNDE[27], LINC00525[28], and MALAT1[29,30] promote oxaliplatin resistance by sponging specific miRNAs. In addition, the lncRNA CCAL facilitates resistance to oxaliplatin in CRC cells by increasing the level of β-catenin expression[31]. The lncRNA LUCAT1 affects oxaliplatin sensitivity through the p53 signalling pathway.
pathway. Knockdown of LUCAT1 renders CRC cells hypersensitive to oxaliplatin treatment[32].

A recent study by Li et al[2] revealed that the lncRNA PRNT is upregulated in oxaliplatin-resistant CRC cells and modulates the expression of HIPK2 by sponging ZNF184, marring bioinformatics analyses with robust in vitro and in vivo experiments. However, there is a pressing need to validate the clinical relevance of the PRNT/ZNF184/HIPK2 axis in a larger cohort of CRC patients. Considering the role of PRNT in chemoresistance, a systematic characterization of lncRNAs may redefine our approach to cancer treatment. Furthermore, examining the interplay between lncRNAs and other signalling pathways could uncover additional layers of regulation and points of intervention.

---

**AUTOPHAGY-RELATED LNCRNAS REGULATE CHEMORESISTANCE IN CRC**

ARlncRNAs can mediate both sides of autophagy and thus can positively or negatively affect drug resistance[20]. Autophagy-mediated drug resistance is a complex phenomenon involving multiple factors, including the recirculation of cytoplasmic components, gene repair mechanisms, alterations in drug concentration and metabolism, changes in the expression or activity of key proteins, and modifications in apoptotic and survival signalling pathways[6].

LncRNA H19 promotes SIRT1-dependent autophagy via miR-194-5p, thereby inducing 5-Fluorouracil (5-FU) resistance in CRC[33]. The knockdown of NEAT1 attenuates autophagy by targeting miR-34a to increase 5-FU sensitivity[34]. SNHG6 may promote chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in CRC cells[35]. In vivo and in vitro, the lncRNA UCA1 promotes autophagy through the miR-23b-3p/ZNF281 axis, which mediates resistance to 5-FU in CRC cells[36]. Similarly, the lncRNA SNHG14 stimulates cellular autophagy through interaction with the miR-186/ATG14 axis to promote cisplatin resistance in CRC[37]. The lncRNA TUG1 targets miR-195-5p and blocks its expression. MiR-195-5p promotes the HDGF/DDX/β-catenin axis, thereby triggering autophagy, which promotes resistance to cisplatin[38] (Figure 1B).

Both recent studies are noteworthy, as they revealed the roles of lncRNAs in CRC progression and treatment resistance. A more comprehensive approach is necessary to elucidate the network of lncRNA interactions in CRC since they focused on individual lncRNA. ARlncRNAs act by regulating specific downstream miRNAs[20]. However, individual lncRNA can regulate more than one miRNA, so broader exploration of the numerous targets or signalling pathways downstream of ARlncRNAs is essential. Furthermore, the interaction between autophagy and chemoresistance remains an underexplored topic, and studies in this area may reveal innovative CRC therapies.

---

**CONCLUSION**

Although modulating chemosensitivity by interfering with lncRNAs involved in the autophagy process is a promising new approach for cancer treatment, multicentre validations based on sufficient samples are still necessary. With our increasing knowledge of lncRNAs in CRC, there is promise that some lncRNAs might be applied in biomarker-directed precision medicine approaches to improve survival outcomes in CRC patients.

---

**FOOTNOTES**

**Author contributions:** Yu JM, Sun CQ, and Liu LX contributed to this paper; Yu JM, Sun CQ, Xu HH, Jiang YL, and Liu LX designed the overall concept and outline of the manuscript; Yu JM, Sun CQ, Jiang XY, Ni SQ, Zhao TY, and Liu LX contributed to the writing, and editing the manuscript, illustrations, and review of literature; and all authors read and approved the final manuscript.

**Supported by** the National Natural Science Foundation of China, No. 81472782; National Clinical Key Specialty Department (Oncology) of China, No. YWC-ZKJS-2023-01; and Research Fund of Yili Institute of Clinical Medicine, No. yl2021ms02.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country of origin:** China

**ORCID number:** Ling-Xiang Liu 0000-0001-8689-1788.

S-Editor: Chen YL
L-Editor: A
P-Editor: Zhao S
REFERENCES


